Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
公司代码BBNX
公司名称Beta Bionics Inc
上市日期Jan 30, 2025
CEOSaint (Sean)
员工数量291
证券类型Ordinary Share
年结日Jan 30
公司地址11 Hughes
城市IRVINE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92618
电话19494277785
网址https://www.betabionics.com
公司代码BBNX
上市日期Jan 30, 2025
CEOSaint (Sean)